Literature DB >> 12032770

Cytokine control of developmental programs in normal hematopoiesis and leukemia.

Joseph Lotem1, Leo Sachs.   

Abstract

The establishment of a system for in vitro clonal development of hematopoietic cells made it possible to discover the cytokines that regulate hematopoiesis. These cytokines include colony stimulating factors and others, which interact in a network, and there is a cytokine cascade which couples growth and differentiation. A network allows considerable flexibility and a ready amplification of response to a particular stimulus. A network may also be necessary to stabilize the whole system. Cells called hematopoietic stem cells (HSC) can repopulate all hematopoietic lineages in lethally irradiated hosts, and under appropriate conditions give rise to neuronal, muscle, and epithelial cells. Granulocyte colony stimulating factor induces migration of both HSC and in vitro colony forming cells from the bone marrow to peripheral blood. Granulocyte colony stimulating factor is also used clinically to repair irradiation and chemotherapy associated suppression of normal hematopoiesis in cancer patients, and to stimulate normal granulocyte development in patients with infantile congenital agranulocytosis. It is suggested that there may also be appropriate conditions under which in vitro colony forming cells have a wider differentiation potential similar to that shown by HSC. An essential part of the developmental program is cytokine suppression of apoptosis by changing the balance in expression of apoptosis inducing and suppressing genes. Decreasing the level of cytokines that suppress therapeutic induction of apoptosis in malignant cells can improve cancer therapy. Cytokines and some other compounds can reprogram abnormal developmental programs in leukemia, so that the leukemic cells differentiate to mature non dividing cells, and this can also be used for therapy. There is considerable plasticity in the developmental programs of normal and malignant cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032770     DOI: 10.1038/sj.onc.1205319

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

1.  Cytokine-mediated increases in fetal hemoglobin are associated with globin gene histone modification and transcription factor reprogramming.

Authors:  Orapan Sripichai; Christine M Kiefer; Natarajan V Bhanu; Toshihiko Tanno; Seung-Jae Noh; Sung-Ho Goh; J Eric Russell; Cheryl L Rognerud; Ching-Nan Ou; Patricia A Oneal; Emily R Meier; Nicole M Gantt; Colleen Byrnes; Y Terry Lee; Ann Dean; Jeffery L Miller
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

2.  Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin.

Authors:  Peter Tsvetkov; Gad Asher; Veronica Reiss; Yosef Shaul; Leo Sachs; Joseph Lotem
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

3.  Towards a systemic paradigm in carcinogenesis: linking epigenetics and genetics.

Authors:  Ernesto Burgio; Lucia Migliore
Journal:  Mol Biol Rep       Date:  2015-04       Impact factor: 2.316

4.  Bone marrow lymphoid and myeloid progenitor cells are suppressed in 7,12-dimethylbenz(a)anthracene (DMBA) treated mice.

Authors:  A U N'jai; M Larsen; L Shi; C R Jefcoate; C J Czuprynski
Journal:  Toxicology       Date:  2010-02-18       Impact factor: 4.221

5.  Induction in myeloid leukemic cells of genes that are expressed in different normal tissues.

Authors:  Joseph Lotem; Hila Benjamin; Dvir Netanely; Eytan Domany; Leo Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

6.  Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.

Authors:  Marco Ragusa; Giuseppe Avola; Rosario Angelica; Davide Barbagallo; Maria Rosa Guglielmino; Laura R Duro; Alessandra Majorana; Luisa Statello; Loredana Salito; Carla Consoli; Maria Grazia Camuglia; Cinzia Di Pietro; Giuseppe Milone; Michele Purrello
Journal:  BMC Cancer       Date:  2010-07-19       Impact factor: 4.430

7.  Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes.

Authors:  Joseph Lotem; Hilah Gal; Rachel Kama; Ninette Amariglio; Gideon Rechavi; Eytan Domany; Leo Sachs; David Givol
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-12       Impact factor: 11.205

8.  P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.

Authors:  Gad Asher; Joseph Lotem; Peter Tsvetkov; Veronica Reiss; Leo Sachs; Yosef Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-21       Impact factor: 11.205

9.  Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages.

Authors:  Tim D Eubank; Ryan D Roberts; Mahmood Khan; Jennifer M Curry; Gerard J Nuovo; Periannan Kuppusamy; Clay B Marsh
Journal:  Cancer Res       Date:  2009-02-17       Impact factor: 12.701

10.  The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages.

Authors:  Anita Gaurnier-Hausser; Vicki L Rothman; Svetoslav Dimitrov; George P Tuszynski
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.